South Shore Capital Advisors’s Merck MRK Stock Holding History

South Shore Capital Advisors’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$449K	Buy	3,498 +90	+3%	+$10.5K	0.3%	77
2026 Q1	$410K	Buy	+3,408	New	+$393K	0.3%	79
2022 Q3	–	Sell	-2,911	Closed	-$265K	–	85
2022 Q2	$265K	Buy	+2,911	New	+$258K	0.55%	60

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

South Shore Capital Advisors's MRK Position: Q2 2026 in Review

South Shore Capital Advisors increased its Merck (MRK) stake by 2.6% in Q2 2026, buying an estimated $10.5K and bringing the position to 3,498 shares worth $449K. The position accounts for 0.3% of the portfolio, ranked #77.

South Shore Capital Advisors first reported a position in MRK in Q2 2022 and has held it in 3 quarters since. 3,841 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

South Shore Capital Advisors held 3,498 shares of Merck worth $449K as of Q2 2026.
South Shore Capital Advisors bought 90 Merck shares in Q2 2026, an estimated $10.5K.
Merck made up 0.3% of South Shore Capital Advisors's portfolio in Q2 2026, its #77 holding.
South Shore Capital Advisors first reported a position in Merck in Q2 2022 and has held it in 3 quarters since.
3,841 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on South Shore Capital Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.